Your session is about to expire
← Back to Search
Other
Diet + Lovastatin + Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
Phase 2
Waitlist Available
Research Sponsored by National Center for Research Resources (NCRR)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
PROTOCOL ENTRY CRITERIA: Cerebrotendinous xanthomatosi
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial will study patients with cerebrotendinous xanthomatosis to see the effects of a cholesterol- and cholestanol-free diet, and the drugs lovastatin and chenodeoxycholic acid, on the biosynthesis of cholesterol and cholestanol, and the turnover of individual sterols and bile acids.
Who is the study for?
This trial is for patients who have been diagnosed with cerebrotendinous xanthomatosis, a rare condition affecting cholesterol and bile acid metabolism. Participants need to follow a special diet free from cholesterol and cholestanol.
What is being tested?
The study aims to see how a diet without cholesterol and cholestanol, along with medications lovastatin and chenodeoxycholic acid, affects the body's production of these substances in people with cerebrotendinous xanthomatosis.
What are the potential side effects?
Potential side effects may include muscle pain or weakness due to lovastatin, as well as digestive issues like stomach pain or constipation from both treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
National Center for Research Resources (NCRR)Lead Sponsor
537 Previous Clinical Trials
317,011 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
985 Previous Clinical Trials
7,385,719 Total Patients Enrolled
William ConnorStudy ChairOregon Health and Science University
2 Previous Clinical Trials
105 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with cerebrotendinous xanthomatosis.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger